TET2 and DNMT3A Mutations in Human T-Cell Lymphoma

Abstract

To the Editor: Despite the poor prognosis of T-cell lymphomas, the genetic basis of these cancers is poorly defined.1 We have found acquired TET2 mutations in both human myeloid cancers2 and T-cell lymphoma.3 TET proteins are involved in the epigenetic control of transcription, at least through the oxidation of methylated cytosines and DNA demethylation.4 The catalytic activity of the TET proteins is inhibited by 2-hydroxyglutarate, an oncogenic metabolite produced by the mutated forms of the IDH1 and IDH2 enzymes. IDH mutations are observed in myeloid cancers, but involvement in T-cell lymphoma has not been reported. We investigated the status . . .